Pay in 4 interest-free payments of $12.00 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
2001 Mar 6
is a protease inhibitor potentially for the treatment of HCV infection
It is highly selective for G9a/GLP over several other protein lysine and arginine methyltransferases
) selectively induces behavioral deficits in hM4Di-expressing monkeys
There is an 87
PQR-309 - CAS# 1225037-39-7 0216 2001 Mar 6PQR 309, CAS No. 1225037 39 7, is an orally bioavailable pan inhibitor of phosphoinositide 3 kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. PI3K mTOR kinase inhibitor PQR 309 inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K mTOR. Activation of
US$ 196.74
US$ 25.54
US$ 132.67
US$ 11.08
US$ 11.24
US$ 1245.52